+

WO2018178989A1 - Méthodes de traitement de mélanome - Google Patents

Méthodes de traitement de mélanome Download PDF

Info

Publication number
WO2018178989A1
WO2018178989A1 PCT/IL2018/050367 IL2018050367W WO2018178989A1 WO 2018178989 A1 WO2018178989 A1 WO 2018178989A1 IL 2018050367 W IL2018050367 W IL 2018050367W WO 2018178989 A1 WO2018178989 A1 WO 2018178989A1
Authority
WO
WIPO (PCT)
Prior art keywords
melanoma
tnfsf4
level
mir
subject
Prior art date
Application number
PCT/IL2018/050367
Other languages
English (en)
Inventor
Raya LEIBOWITZ-AMIT
Janos ROSZIK
Elizabeth Grimm
Original Assignee
Tel Hashomer Medical Research Infrastructure And Services Ltd.
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Research Infrastructure And Services Ltd., Board Of Regents, The University Of Texas System filed Critical Tel Hashomer Medical Research Infrastructure And Services Ltd.
Publication of WO2018178989A1 publication Critical patent/WO2018178989A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention discloses methods for improved detection of melanoma, optimization of melanoma treatment regimens and methods for treating melanoma.
  • stage III melanoma namely, involvement of regional lymph nodes without distant metastasis
  • Ulceration of the primary tumor has been long known to be a negative prognostic factor, and ulceration status also serves as a predictive factor for response to adjuvant therapy with interferon-alpha in stage III patients.
  • Immune checkpoint inhibitors namely, monoclonal antibodies that increase cancer immunogenicity by decreasing inhibitory signals between cancerous cells and lymphocytes - were shown to have significant activity in metastatic melanoma (Jessurun et al., Front. Oncol., 7 (article 233): 1-12, 2017).
  • the anti-PDl monoclonal antibody nivolumab was shown to be superior to ipilimumab in prolonging progression-free survival (Weber et al, N. Engl. J. Med., 377:1824-1835, 2017). Notwithstanding this major advancement, the clinical use of monoclonal antibodies is hampered by their significant toxicity and enormous costs.
  • Micro-RNAs are short non-coding RNAs known to have fundamental roles in the regulation of gene expression. miRNAs have been widely implicated in physiological processes, such as embryonal development and in pathological processes, such as cancerous transformation and progression. For example, Mir-424, one of the miRNAs from the mir- 15a/16-l (comprising of 8 miRNAs with an identical seed sequence) was implicated in the regulation of the checkpoint mRNAs B7.1 and PD-IL in ovarian cancer. The transcription factor NF-kB was shown to upregulate the expression of mir-16 in a gastric cancer model.
  • TNFSF4 Tumor Necrosis Factor Superfamily Member 4
  • TNFSF4 provides an improved assessment of responsiveness to immunotherapy in advanced (stage III or IV) patients.
  • TNFSF4 provides a new platform for selection of a subpopulation of melanoma patients that can benefit from immunotherapy treatment, thus improving the benefit-risk ratio.
  • use of TNFSF4 as disclosed herein point to patients in need of an intensified-treatment with combined immunotherapy (anti-PDl and anti-CTLA4 antibodies).
  • a method for treating melanoma in a subject in need thereof comprising administering a pharmaceutical composition comprising mono-immunotherapy to a subject having a level of TNFSF4 mRNA or protein above a reference value.
  • the level of TNFSF4 mRNA or protein above a reference value is obtained by a method comprising: providing a sample comprising biological material from the subject; determining, in the biological material, the level of TNFSF4 mRNA or protein; and comparing the level of TNFSF4 mRNA or protein to a reference value.
  • the sample is a biopsy derived from a skin lesion.
  • the biological material is RNA and the level of TNFSF4 is the level of TNFSF4 mRNA or a level corresponding to the level of TNFSF4 mRNA.
  • the biological material comprises proteins and the level of TNFSF4 is the level of TNFSF4 protein or a level corresponding to the level of TNFSF4 protein.
  • the melanoma is stage III or IV melanoma.
  • the melanoma is selected from superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma and nodular melanoma.
  • the mono-immunotherapy comprises at least one anti- PD1 antibody.
  • the mono-immunotherapy comprises at least one anti- CTLA4 antibody.
  • the method further comprising administering to said subject a pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15a/16-l family in a plurality of cell within the skin lesion.
  • said agent is an siRNA.
  • said siRNA is selected from SEQ ID NO: 1 and SEQ ID NO: 2.
  • said at least one micro RNA from the mir-15a/16-l family is mir-16.
  • a method for treating melanoma in a subject in need thereof comprising administering a pharmaceutical composition comprising combined immunotherapy to a subject having expression level of TNFSF4 mRNA or level of TNFSF4 protein below a reference value.
  • the melanoma is stage III or IV melanoma.
  • the combined immunotherapy comprises at least one anti-CTLA4 antibody and at least one anti-PDl antibody.
  • the combined immunotherapy comprises ipilimumab and nivolumab or ipilimumab and pembrolizumab.
  • a method for treating a subject having melanoma comprising administering to the subject a pharmaceutical composition comprising a compound that down-regulates the expression of the at least one micro RNA from the mir-15 a/16-1 family.
  • the compound is an inhibitor of MAP3K7. According to some embodiments, the compound comprises at least one of de- methylating compounds and HDAc inhibitors.
  • the compound comprises at least one de-methylating compound.
  • the at least one de-methylating compound is 5- azacytidine.
  • the compound comprises at least one HDAc inhibitor.
  • the at least one HDAc inhibitor is phenyl-butyric acid or valproic acid.
  • the compound comprises one or more of de- methylating compounds and HDAc inhibitor.
  • said subject is having a skin lesion and wherein administering comprises transfecting a plurality of melanoma cells within the lesion with a vector comprising at least one siRNA that inhibits at least one micro RNA from the mir- 15a/16-l family.
  • the at least one siRNA is selected from SEQ ID NO: 1 and SEQ ID NO: 2.
  • FIGs. 1E-1F present TNFSF4 mRNA expression and TNFSF4 protein levels in melanoma cell lines.
  • FIG. 2 presents TNFSF4 expression in malignant melanoma, lymphocytes and other cell types.
  • FIG. 3 presents TNFSF4 expression in non-ulcerated and ulcerated primary lesions and metastasis.
  • FIGs. 4A-4C present survival rates with ulceration (U) or without ulceration (N) in subjects having melanoma at all stages (Fig. 4A), at Stage II (Fig. 4B) and at Stage III (Fig. 4C).
  • FIGs. 5D-5E present overall survival (OS) and progression free survival (PFS) of patients with metastatic (stage IV) melanoma treated with anti-PDl antibody, having TNFSF4 mRNA expression levels higher than median - H (broken lines), intermediate - I (dotted lines) and lower than median - L (solid lines).
  • OS overall survival
  • PFS progression free survival
  • FIGs. 6A-6I present Spearman rho correlations in the expression of pairs of 18 checkpoint mRNAs in melanoma cell lines.
  • FIGs. 7A-7C present Spearman correlation in the expression of checkpoint mRNAs and mir- 16-1 in 17 melanoma cell lines.
  • FIG. 8 presents survival rate in stage III melanoma patients having high mir- 16 (H) and low mir-16 (L).
  • FIGs. 9A-9C present the combination of mir-16-1 expression and three mRNAs as a prognostic marker in melanoma: TNFSF4 (Fig. 9A), CD274 (Fig. 9B) and CD80 (Fig. 9C); mir low, mRNA high (LH); both mir and mRNA high (HH); both mir and mRNA low (LL); mir high, mRNA low (HL).
  • FIGs. 1 OA- IOC present the combination of mir-16-1 expression and three mRNAs as a prognostic marker in melanoma: CD86 (Fig. 10A), PDCD1LG2 (Fig. 10B) and C 10orf54 (Fig. lOFC); mir low, mRNA high (LH); both mir and mRNA high (HH); both mir and mRNA low (LL); mir high, mRNA low (HL).
  • FIG. 11 presents the percentage change (relative to control) in the expression of checkpoint mRNAs following transient inhibition of mir- 16 in 6 melanoma cell lines.
  • FIGs. 12-13 present the effect of MA3K7 inhibition with increasing levels of 5Z-7- oxozeaenol on the expression levels of B7.1 in two melanoma cell lines: SB2 and SK-mel, respectively.
  • FIG. 14 presents the relative expression of mir- 16 in four melanoma cell lines following addition of 5-azacytidine and phenyl-butyric acid (PBA).
  • FIGs. 15A-15B present the effect of Mir- 16 on the 3'UTR of the mRNAs of two co- stimulatory checkpoint genes - CD40 and CD80, respectively, using a luciferase reporter assay.
  • FIGs. 15C-15E present the effect of an siRNA mimic or inhibitor on the expression of mir-16, CD40 and CD80, respectively.
  • the methods disclosed herein are based on the understanding of the crosstalk between the immune system and cancer and the realization that cancer cells and lymphocytes communicate through cell-cell interactions, designated 'the immunological synapse', within the tumor microenvironment.
  • the immunological synapse comprises of both co-stimulatory and co-inhibitory transmembrane proteins, that all serve to modulate the signal transmitted from the cancer cell to the lymphocyte towards either activation energy or exhaustion.
  • Several checkpoint mRNAs are under transcriptional regulation of the transcription factor NF-kB, which has been implicated in the determination of cancer immunogenicity.
  • TNFSF4 also known as OX40L
  • OX40L is a co-stimulatory checkpoint gene that can interact with its cognate receptor, TNFRSF4 (OX40) on lymphocytes.
  • Immune checkpoint inhibitors namely, monoclonal antibodies that increase cancer immunogenicity by decreasing inhibitory signals between cancerous cells and lymphocytes, have revolutionized treatment in melanoma, and led to unprecedented improvement in the therapy outcome of metastatic disease (stage IV).
  • the response rate to single-agent anti- CTLA4 antibodies e.g. ipilimumab
  • single-agent anti-PDl antibodies nivolumab or pembrolizumab
  • the response rate to dual checkpoint inhibition with the combination of ipilimumab and nivolumab is as high as 60-70%, albeit at a cost of significant toxicity.
  • stage III melanoma melanoma that has spread to regional lymph nodes but not to distant organs.
  • adjuvant ipilimumab improved the 5-year survival from -55% to -65%, which is both statistically and clinically significant.
  • adjuvant ipilimumab is currently not routinely used in stage III melanoma patients for two main reasons - first, this drug has significant toxicity, with a fatality rate of a little more than 1 %. Second, its cost is enormous, and current drug reimbursement schemes across the world have not indorsed this drug.
  • stage III melanoma the anti- PDl antibody nivolumab was shown to be superior to ipilimumab in prolonging progression- free survival.
  • patients with stage III melanoma that poorly respond to nivolumab may need dual immunotherapeutic treatment, for example, combined immunotherapy with nivolumab and ipilimumab.
  • the routine use of ipilimumab for all populations of stage III melanoma patients is almost not feasible. Accordingly, in most countries, these patients are monitored without active treatment, or receive interferon-alpha, which has only a marginal survival benefit while associated with significant toxicity, or receive nivolumab, which has still not been shown to improve overall survival. Identifying in advance the subpopulation of patients that will not benefit from mono immunotherapy, and may benefit from combined immunotherapy would improve survival and would reduce the overall cost.
  • the methods disclosed herein permit the personalization of therapy amongst melanoma patients, wherein a subject's biomarker profile is predictive of, or indicative of, treatment efficacy and/or survival.
  • the methods disclosed herein can be used in combination with assessment of conventional clinical factors, such as tumor size, tumor grade, lymph node status, family history, and analysis of expression level of additional biomarkers. In this manner, the methods of the present disclosure permit a more accurate evaluation of prognosis and cancer therapy effectiveness.
  • the methods disclosed herein include determining the level of TNFSF4 protein or the expression levels of the mRNA transcripts for TNFSF4 in a sample from a patient with melanoma.
  • Determining the level of TNFSF4 protein or mRNA does not require identification of the entire amino sequence of the protein or the entire ribonucleic acid sequence of the RNA (or the corresponding nucleic acid). Rather, determining the level of TNFSF4 protein or mRNA includes determining a fragment of the protein, mRNA or the corresponding cDNA, which is sufficient for identifying the presence of TNFSF4 protein or mRNA. The fragment may be a distinct epitope identified by an immunoassay or a segment for hybridization which is sufficient for determining the presence or level of TNFSF4. Accordingly, the term "TNFSF4 protein" includes a fragment of the TNFSF4 protein. Similarly, the term TNFSF4 mRNA includes a fragment of TNFSF4 mRNA, or a fragment of DNA corresponding to TNFSF4 mRNA.
  • TNFSF4 refers to TNFSF4 mRNA or TNFSF4 protein.
  • the methods disclosed herein include determining the level of TNFSF4 protein in a sample from a patient with melanoma.
  • the methods disclosed herein include determining the expression levels of the mRNA transcripts for TNFSF4 in a sample from a patient with melanoma.
  • the methods described herein includes steps comprising determining the expression level of TNFSF4 in a test sample obtained from a subject; wherein an increase in the TNFSF4 expression level relative to a reference level indicates the subject can benefit from mono immunotherapy for the treatment of melanoma.
  • the expression level of TNFSF4 can be determined by measuring the level of TNFSF4 RNA transcript.
  • the RNA transcript level can be measured using reverse transcription polymerase chain reaction (RT-PCR).
  • the expression level of TNFSF4 can be determined by measuring the level of TNFSF4 protein.
  • the protein level can be measured using immunochemistry.
  • the protein level can be measured using a small molecule which specifically binds to TNFSF4 and which is detectably labeled.
  • the sample can comprise a material selected from the group consisting of: a biofluid sample, serum, plasma, urine, saliva and a tumor sample.
  • the methods of the present disclosure can be used to assist in selecting appropriate courses of treatment and to identify patients that would benefit from a particular course of therapy.
  • determining the level of TNFSF4 protein or mRNA as described herein provides insight into which cancer treatment regimen will be most effective for the patient. This information can be used to generate treatment plans for the patient to prolong survival and minimize side effects or cancer therapy related toxicity.
  • a method of predicting responsiveness of melanoma in a subject to immunotherapy comprising: obtaining a sample from the subject; measuring TNFSF4 protein level or the mRNA expression level of TNFSF4 in the sample; generating a comparison of the level of TNFSF4 in the sample to a reference level of TNFSF4; and using said comparison to predict the responsiveness of the melanoma to treatment with mono-immunotherapy, wherein high levels of TNFSF4 are predictive of responsiveness of the melanoma to treatment with mono-immunotherapy and wherein low levels of TNFSF4 are predictive of lack of responsiveness of the melanoma to treatment with mono-immunotherapy.
  • low levels of TNFSF4 are predictive of responsiveness of the melanoma to treatment with combined-immunotherapy
  • mono immunotherapy refers to treatment regimen with one monoclonal antibody.
  • Mono-immunotherapy includes any one of anti-PDl and anti-CTLA4 monoclonal antibodies.
  • anti-PDl comprises any one or more of nivolumab and pembrolizumab.
  • anti-CTLA4 comprises ipilimumab.
  • combined immunotherapy refers to treatment regimen with a combination of monoclonal antibodies, such as, a combination of anti-PDl and anti-CTLA4 monoclonal antibodies.
  • low levels of TNFSF4 indicate unfavorability of including mono-immunotherapy in the melanoma therapy.
  • identifying a subject in need of mono-immunotherapy for melanoma comprises: determining the expression level of TNFSF4 in a test sample obtained from a subject, wherein the subject is identified as being in need of mono- immunotherapy for melanoma if the expression level of TNFSF4 is increased relative to a reference level.
  • identifying a subject in need of combined- immunotherapy for melanoma comprises: determining the expression level of TNFSF4 in a test sample obtained from a subject, wherein the subject is identified as being in need of combined-immunotherapy for melanoma if the expression level of TNFSF4 is decreased relative to a reference level.
  • predicting responsiveness refers to providing a probability based analysis of how a particular subject diagnosed with melanoma and expected to receive treatment (immunotherapy) will respond to a cancer therapy, specifically, to mono- immunotherapy.
  • the prediction of responsiveness is not a guarantee or absolute, only a statistically probable indication of the responsiveness of the subject.
  • the prediction of responsiveness to a cancer therapy may indicate that the subject is likely to be responsive to mono-immunotherapy or alternatively may indicate that the subject is not likely to be responsive to mono-immunotherapy.
  • the prediction may indicate that inclusion of mono-immunotherapy in a cancer therapy regimen may be counter-productive and lead to a worse result for the subject than if no therapy was used or a placebo was used.
  • Responsiveness includes but is not limited to, any measure of a likelihood of clinical benefit.
  • clinical benefits include an increase in overall survival, an increase in progression free survival, an increase in time to progression, increased tumor response, decreased symptoms, or other quality of life benefits.
  • a method for treating melanoma in a subject in need thereof comprising administering a pharmaceutical composition comprising mono-immunotherapy to a subject having expression level of TNFSF4 mRNA or level of TNFSF4 protein above a reference value.
  • lack of responsiveness to mono-immunotherapy indicates a significant increase in clinical benefit to treatment with combined therapy.
  • the method disclosed herein provide a clinical guidance to the selection of treatment regimen.
  • the terms "subject” and “patient” are used interchangeably and refer to both human and non-human animals.
  • the subject is a human patient. More preferably, the subject is a human patient diagnosed with melanoma, undergoing, or about to undergo, a cancer treatment regimen.
  • said subject is human.
  • said subject is a human patient diagnosed with melanoma, undergoing, or about to undergo, cancer treatment.
  • the pharmaceutical composition comprises at least one anti-PDl antibody. According to some embodiments, the pharmaceutical composition comprises nivolumab. According to some embodiments, the pharmaceutical composition comprises nivolumab as the only active ingredient. According to some embodiments, the pharmaceutical composition comprises pembrolizumab. According to some embodiments, the pharmaceutical composition comprises pembrolizumab as the only active ingredient.
  • the pharmaceutical composition comprises at least one anti-CTLA4 antibody. According to some embodiments, the pharmaceutical composition comprises ipilimumab. According to some embodiments, the pharmaceutical composition comprises ipilimumab as the only active ingredient.
  • the prognosis is independent of cancer therapeutic or cancer treatment regimen employed.
  • the subject may have localized, advanced or metastatic melanoma.
  • the method includes determining or detecting the expression level of TNFSF4 mRNA, or the level of TNFSF4 protein, in a sample from the subject. The level of the biomarker present in the sample is then compared to reference levels as described below. Finally, by comparison to the reference levels a prognosis for the subject can be determined .
  • the level of TNFSF4 is measured, and high level is indicative of a better prognosis and low level is indicative of poor prognosis.
  • Treatment plans may be developed using the predictions of the responsiveness of the cancer to treatment with a cancer therapy including mono-immunotherapy obtained using the methods described herein to determine whether treatment of the subject with mono- immunotherapy may be beneficial.
  • the treatment plan will include mono-immunotherapy if such therapy is expected to be beneficial and the treatment plan will include combined- immunotherapy if it is predicted to be clinically beneficial to the subject as described above.
  • a method for detecting melanoma in a subject comprising:
  • said providing a sample is obtaining a biopsy from a skin lesion.
  • said sample is blood, plasma, serum or urine.
  • the genetic material is RNA.
  • the level of TNFSF4 protein in a sample from the subject is determined.
  • the presence or absence of TNFSF4 protein may be determined by various methods, including, but not limited to, methods that are compatible with the detectable label used, e.g., microscopy, radiography, scintillation counting, immunohistochemistry, etc.
  • a level of TNFSF4 protein is compared to a level of one or more reference samples, and the results evaluated to facilitate the determination of treatment regimen as disclosed herein. Control samples can be run in parallel to provide comparison levels, or the levels of specific control level may be provided as standard values for purposes of comparison.
  • detecting refer to both quantitative and qualitative determinations and as such, the term “determining” is used interchangeably herein with “assaying,” “measuring,” and the like. Where a quantitative determination is intended, the phrase “determining an amount” of an analyte and the like is used. Where either a qualitative or a quantitative determination is intended, the phrase “determining a level" of an analyte or “detecting” an analyte is used.
  • the level of TNFSF4 protein in a sample from the subject may be assessed using an immunoassay.
  • immunoassay Exemplary formats include, but are not limited to, competitive binding assays in the presence of different amounts of a competitor protein which competes for binding to the TNFSF4 protein, and lateral flow immunoassay test (LFIA), also known as the immunochromatographic assay.
  • LFIA lateral flow immunoassay test
  • the competitor molecule can be labeled.
  • immunoassays e.g., Western blots
  • protein gels or protein spots on filters may be adapted for use in the methods disclosed herein.
  • the detection assays can be carried out in solution.
  • Exemplary assays and reagents compatible for use in protein level assessment assays are known in the art and may be adapted for use in the methods disclosed herein.
  • the level of TNFSF4 protein in the sample may be determined by Mass spectrometry- based methods. Mass spectrometry can be combined with immunoassays, e.g., by first forming specific biomarker (TNFSF4 protein)-antibody immunocomplexes, and detecting the presence or absence of the specific immunocomplexes by mass spectroscopy.
  • an anti-biomarker antibody may be used to capture the TNFSF4 protein.
  • the anti-biomarker antibody may be bound to a support, such as a bead, a plate, a membrane or a chip. After unbound materials are washed away, the captured biomarkers may be detected by mass spectrometry. Examples of mass spectrometers include time-of-flight, magnetic sector, quadmpole filter, ion trap, ion cyclotron resonance, electrostatic sector analyzer and hybrids of these.
  • the mass spectrometer can be a laser desorption/ionization (LDI) mass spectrometer.
  • the level of TNFSF4 may be determined by immunohistochemistry. Immunohistochemistry involves the process of selectively imaging TNFSF4 in the sample by exploiting labeled (directly or indirectly) anti-TNFSF4 antibodies that specifically bind to TNFSF4 in the sample. Visualizing an antibody- antigen interaction may be accomplished in a number of ways. For instance, an antibody is conjugated to an enzyme, such as peroxidase that can catalyze a color-producing reaction. Alternatively, the antibody may also be tagged to a fiuorophore, such as fluorescein or rhodamine.
  • the expression level of TNFSF4 mRNA in a sample from the subject is determined. Then the level in the sample from the subject is compared to a reference level of the biomarker (TNFSF4 mRNA).
  • TNFSF4 mRNA can be detected on a nucleic acid level.
  • detecting or determining expression is intended determining the quantity or presence of an RNA transcript for TNFSF4.
  • detecting expression encompasses instances where a biomarker is determined not to be expressed, not to be detectably expressed, expressed at a low level, expressed at a normal level, or overexpressed.
  • RNA-seq RNA-seq
  • the reference level may be determined empirically such as it was in the Examples, by comparison to the levels found in a set of samples from cancer patients treated with cancer therapies, specifically, with mono immunotherapy with known clinical outcomes for the patients. The results may be analyzed by dividing the data to quartiles, each corresponding to the level of the marker, such that, the upper quartile corresponds to high expression levels, the lowest quartile to low expression levels and the remaining quartile (2 nd and 3 rd ) to intermediate expression levels.
  • the reference level may be a level of the biomarker found in samples, such as plasma samples, which becomes a standard and can be used as a predictor for new samples. For example, the cut-off levels reported in the Examples may now serve as reference levels for comparison.
  • the reference level is determined by analysis of a set of samples from melanoma patients treated with cancer therapies including or excluding immunotherapy with known outcomes.
  • the reference level can comprise the level of TNFSF4 (e.g. RNA transcript or protein) in a sample of the same type taken from a subject, or a plurality of subjects, not exhibiting any signs or symptoms of melanoma.
  • TNFSF4 e.g. RNA transcript or protein
  • TNFSF4 mRNA expression or TNFSF4 protein level in some instances may be normalized against the expression levels of all RNA transcripts in the sample, or against a reference set of RNA transcripts in the sample or against the level of proteins in the sample.
  • the level of TNFSF4 is indicative of the prognosis for the subject or predictive of the effectiveness of a particular treatment, as disclosed herein.
  • the reference value corresponds to the median of the results obtained during the study described in Example 1.
  • the methods described herein further comprise a step of obtaining a sample from a subject.
  • prognostic and predictive performance of TNFSF4 is assessed and presented as Kaplan-Meier curves or plots.
  • Methods for assessing statistical significance are well known in the art and include, for example, using a log-rank test, Student T-test, a Cox proportional hazards model and Kaplan-Meier curves.
  • a p- value of less than 0.05 constitutes statistical significance.
  • said melanoma is selected from superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma and nodular melanoma.
  • the melanoma is stage III or stage IV melanoma.
  • Melanoma staging methods vary but are all approaches rely mostly on the thickness of the tumor, also known as Breslow' s thickness or Breslow' s depth and the appearance of microscopic ulceration (meaning that the epidermis on top of a major portion of the melanoma is not intact).
  • Early melanomas (clinical stages I and II) are commonly determined based on T categories.
  • the method further comprises determining ulceration of the primary tumor, wherein ulceration together with an expression level of TNFSF4 mRNA in the sample higher from the reference value, is indicative of subject's responsiveness to 'mono immunotherapy' treatment.
  • tumor melanoma (or melanoma tumor).
  • Ulceration typically refers to a breakdown of the skin over the melanoma. Melanomas that are ulcerated tend to have a worse outlook. Ulceration is commonly one of the aspects that define staging of melanoma in the T categories, which include:
  • the melanoma is less than or equal to 1.0 mm thick. It is ulcerated and/or the mitotic rate is equal to or greater than l/mm2.
  • the melanoma is between 1.01 and 2.0 mm thick without ulceration.
  • the melanoma is between 1.01 and 2.0 mm thick with ulceration.
  • the melanoma is between 2.01 and 4.0 mm thick without ulceration.
  • the melanoma is between 2.01 and 4.0 mm thick with ulceration.
  • the melanoma is thicker than 4.0 mm without ulceration.
  • the melanoma is thicker than 4.0 mm with ulceration.
  • the tumor spreads either to the lymph nodes or to the skin between the primary tumor and the nearby lymph nodes.
  • a tumor is assigned to Stage III if it has metastasized or spread beyond the original (primary) tumor site. This can be determined by examining a biopsy of the node nearest the tumor, known as the sentinel node. Such a biopsy may be done when a tumor is more than 1 mm in thickness, or when a thinner melanoma shows evidence of ulceration.
  • In-transit or satellite metastases are also included in Stage III. In this case, the spread is to skin or underlying (subcutaneous) tissue for a distance of more than 2 cm from the primary tumor, but not to the regional lymph nodes.
  • Metastases may be so tiny that they can be seen only through the microscope (micrometastases).
  • the advancement of a tumor into Stage III depends on factors such as whether the metastases are in-transit or have reached the nodes, the number of metastatic nodes, the number of cancer cells found in them, and whether or not they are micrometastases or can be seen with the naked eye.
  • Stage IV melanoma has metastasized to lymph nodes distant from the primary tumor or to internal organs, most often the lung, followed in descending order of frequency by the liver, brain, bone, and gastrointestinal tract.
  • the two main factors in determining how advanced the melanoma is into Stage IV are the site of the distant metastases (e.g. nonvisceral, lung) and elevated serum lactate dehydrogenase (LDH) level.
  • the distant metastases e.g. nonvisceral, lung
  • LDH serum lactate dehydrogenase
  • said sample is a sample from at least one melanoma tumor.
  • the sample is a plurality of samples obtained from at least one tumor.
  • the sample is a plurality of samples, each obtained from a different tumor in the same subject.
  • the sample is a plurality of samples, each obtained from a different tumor, where at least one of said plurality of tumors is a primary tumor.
  • a method for treating melanoma comprising down-regulating the expression of at least one micro RNA from the mir-15a/16-l family.
  • a method for treating melanoma comprising administering to a subject in need thereof a pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15 a/16-1 family.
  • Micro-RNAs are short non-coding RNAs known to have fundamental roles in the regulation of gene expression, and have been widely implicated in physiological processes such as embryonal development and in pathological processes such as cancerous transformation and progression. miRNAs can bind to the 3'UTR of mRNAs and lead to their post-transcriptional degradation or to translational repression. Mir-424, one of the miRNAs from the mir-15a/16-l (comprising of 8 miRNAs with an identical seed sequence) was implicated in the regulation of the checkpoint mRNAs B7.1 and PD-1L in ovarian cancer. The transcription factor NF-kB was shown to upregulate the expression of mir-16 in a gastric cancer model.
  • a compound that down regulates at least one micro RNA from the mir-15a/16-l family for the treatment of melanoma.
  • the technology described herein relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound that down regulates at least one micro RNA from the mir-15a/16-l family for the treatment of melanoma, and optionally a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is well known in the art.
  • the pharmaceutical composition comprising of a compound that down regulates at least one micro RNA from the mir-15a/16-l family as described herein can be a parenteral dose form. Since administration of parenteral dosage forms typically bypasses the patient's natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. In addition, controlled- release parenteral dosage forms can be prepared for administration to the patient.
  • a compound that down regulates at least one micro RNA from the mir-15a/16-l family as described herein can be administered in a liposome formulation.
  • lipid vesicle or “liposome” refers to vesicles surrounded by a bilayer formed of lipid components usually including lipids optionally in combination with non-lipidic components.
  • the interior of a vesicle is generally aqueous.
  • the methods described herein comprise administering an effective amount of compositions described herein, e.g. a composition comprising a compound that down regulates at least one micro RNA from the mir-15a/16-l family to a subject in order to treat melanoma.
  • compositions described herein e.g. a composition comprising a compound that down regulates at least one micro RNA from the mir-15a/16-l family
  • the terms “treat,” “treatment,” “treating,” or “amelioration” are interchangeable and refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with melanoma.
  • the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder associated with melanoma.
  • Treatment is generally "effective” if one or more symptoms and/or clinical markers are reduced.
  • treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment.
  • Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and/or decreased mortality, whether detectable or undetectable.
  • treatment also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).
  • the term "pharmaceutical composition” refers to the one or more active agents in combination with a pharmaceutically acceptable carrier e.g. a carrier commonly used in the pharmaceutical industry.
  • a pharmaceutically acceptable carrier e.g. a carrier commonly used in the pharmaceutical industry.
  • pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • administering refers to the placement of a compound as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site.
  • Pharmaceutical compositions comprising the compounds disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject, e.g. parenteral, intravenous, intralesional, or intratumoral.
  • an effective amount refers to the amount of a therapy needed for treatment of melanoma, and relates to a sufficient amount of pharmacological composition to provide the desired effect.
  • the term "therapeutically effective amount” therefore refers to an amount of a therapy that is sufficient to cause a particular effect when administered to a typical subject.
  • An effective amount as used herein, in various contexts, would also include an amount sufficient to delay the development of melanoma, alter the course of melanoma (for example, but not limited to, slowing the progression of the disease), or reverse the course of the disease. Thus, it is not generally practicable to specify an exact "effective amount”. However, for any given case, an appropriate "effective amount” can be determined by one of ordinary skill in the art using only routine experimentation.
  • an effective amount can be an amount which causes a skin lesion growth to decrease or, at least, to increase at a lower rate than it would be expected to increase in a subject not receiving a composition as described herein. In some embodiments, an effective amount can be an amount which causes a lessening of pain as compared to the level of pain experienced by a subject prior to administration of a composition as described herein. In some embodiments, an effective amount can be an amount that decreases the amount of mir-16 by a statistically significant amount.
  • Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dosage can vary depending upon the dosage form employed and the route of administration utilized.
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
  • Compositions and methods that exhibit large therapeutic indices are preferred.
  • a therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of an therapeutic agent which achieves a half- maximal inhibition of symptoms) as determined in cell culture, or in an appropriate animal model.
  • IC50 i.e., the concentration of an therapeutic agent which achieves a half- maximal inhibition of symptoms
  • Levels in plasma can be measured, for example, by high performance liquid chromatography.
  • the effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
  • an effective dose of a composition comprising a compound that down regulates at least one micro RNA from the mir-15a/16-l family as described herein can be administered to a patient once.
  • an effective dose of a composition comprising a compound that down regulates at least one micro RNA from the mir-15 a/16-1 family can be administered to a patient repeatedly.
  • down-regulating comprises administering to the subject a pharmaceutical composition comprising a compound that down-regulates the expression of the at least one micro RNA from the mir-15a/16-l family.
  • the compound is an inhibitor of MAP3K7.
  • the compound comprises one or more of de-methylating compounds and histone deacetylase inhibitors (HDAc).
  • Demethylating compounds can inhibit methylation, resulting in the expression of the previously hypermethylated silenced genes.
  • Cytidine analogs such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine) are the most commonly used demethylating compounds. These compounds work by binding to the enzymes that catalyse the methylation reaction, DNA methyltransferases.
  • the de-methylating compound is selected from 5- azacytidine and 5-azadeoxycytidine. According to some embodiments, the de-methylating compound is 5-azacytidine.
  • Histone deacetylase (HDAc) inhibitors is a group of 'targeted' anticancer agents. There are about 18 HDACs, which are generally divided into four classes, based on sequence homology to yeast counterparts.
  • Classical HDACi such as the hydroxamic acid- based vorinostat (also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD+-dependent class III enzymes.
  • HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death. Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function.
  • HDACs are also referred to as lysine deacetylases.
  • HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species (ROS)- induced cell death, mitotic cell death and senescence.
  • ROS reactive oxygen species
  • normal cells are relatively more resistant to HDACi-induced cell death.
  • the HDAC inhibitor is phenyl-butyric acid or valproic acid.
  • down-regulating comprises transfecting the melanoma cells with an siRNA that inhibits at least one micro RNA from the mir-15a/16-l family.
  • the siRNA comprises a ribonucleotide sequence comprising CGCCUUTUTTTUCGTGCTGCTU (SEQ ID NO: l) or GCGGUUAUAAAUGCACGACGAU (SEQ ID NO: 2).
  • the siRNA comprises SEQ ID NO:l .
  • the siRNA comprises SEQ ID NO:2.
  • the method further comprises co-administering to the subject said compound that down-regulates the expression of the at least one micro RNA from the mir-15a/16-l family and at least one anti-melanoma therapeutic agent.
  • the at least one anti-melanoma therapeutic agent is selected from the group consisting of at least one anti-PDl monoclonal antibody, at least one anti-CTLA4 monoclonal antibody monoclonal antibody and a combination thereof.
  • the at least one micro RNA from the mir-15a/16-l family is mir-16.
  • a method for treating melanoma in a subject in need thereof comprising: determining the expression level of TNFSF4 mRNA or level of TNFSF4 protein in a sample obtained from a subject; and administering a pharmaceutical composition comprising mono-immunotherapy and a pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15a/16-l family, to a subject having expression level of TNFSF4 mRNA or level of TNFSF4 protein above a reference value.
  • said administering comprises administering a pharmaceutical composition comprising mono-immunotherapy and an agent capable of down- regulating the expression of at least one micro RNA from the mir-15a/16-l family.
  • mono-immunotherapy for use in the treatment of melanoma having expression level of TNFSF4 mRNA or level of TNFSF4 protein above a reference value.
  • combined-immunotherapy for use in the treatment of melanoma having expression level of TNFSF4 mRNA or level of TNFSF4 protein below a reference value.
  • a pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15a/16-l family for use in the treatment of melanoma.
  • a first pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15a/16-l family and a second pharmaceutical composition comprising mono- immunotherapy for use in the treatment of melanoma having expression level of TNFSF4 mRNA or level of TNFSF4 protein above a reference value.
  • a pharmaceutical composition comprising an agent capable of down-regulating the expression of at least one micro RNA from the mir-15a/16-l family and mono-immunotherapy for use in the treatment of melanoma having expression level of TNFSF4 mRNA or level of TNFSF4 protein above a reference value.
  • kits for detecting melanoma in a subject comprises a first container comprising means for evaluating the amount of TNFSF4 mRNA, TNFSF4 protein or fragments thereof in biological materials; indication of a threshold level for TNFSF4 and instructions manual, wherein level of TNFSF4 in the sample higher than the reference value, is indicative of the presence of melanoma.
  • the kit further comprises a sample comprising biological material from a subject having at least one skin lesion.
  • the sample is a biopsy of the at least one skin lesion.
  • the means for evaluating the amount of TNFSF4 mRNA or a fragment thereof the sample comprise materials for RNA purification and primers for amplification of TNFSF4 mRNA by qRT-PCR.
  • the means for evaluating the amount of TNFSF4 protein or a fragment thereof in the sample comprise materials for protein purification and agents for immunohistochemistry.
  • a kit for treating a subject having at least one melanoma lesion comprising a compound that down-regulates at least one micro RNA from the mir-15a/16-l family.
  • the compound is an inhibitor of MAP3K7.
  • the compound comprises at least one of de-methylating compounds and HDAc inhibitors.
  • the compound comprises at least one de-methylating compound.
  • the at least one de-methylating compound is 5-azacytidine.
  • the compound comprises at least one HDAc inhibitor.
  • the at least one HDAc inhibitor is phenyl-butyric acid or valproic acid.
  • the compound comprises one or more of de-methylating compounds and HDAc inhibitor.
  • the kit further comprises at least one anti-melanoma immuno-therapeutic agent.
  • the at least one anti-melanoma immuno-therapeutic agent is an anti-PD-1 or an anti-CTLA-4.
  • the at least one anti-melanoma immuno-therapeutic agent is selected from the group consisting of: ipilimumab, nivolumab and pembrolizumab.
  • the kit comprises a vector comprising at least one si- RNA that inhibits at least one micro RNA from the mir-15a/16-l family.
  • the at least one siRNA is selected from SEQ ID NO: l and SEQ ID NO:2.
  • the vector is a plasmid.
  • a compound that down regulates at least one micro RNA from the mir-15a/16-l family in a melanoma lesion for the treatment of melanoma.
  • a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof .
  • method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
  • Bioinformatics analyses of the expression of mRNAs and miRNAs from 451 samples was performed using the melanoma TCGA database. Correlation coefficients between the expression of mRNAs or mRNAs/miRNAs were calculated using the Spearman rho method. Survival analysis was performed using the Kaplan- Meier method resulting with survival curves of survival time (months) vs. relative survival rate (a fraction of alive (or disease-free) patients per month relative to the initial no. of patients that were analyzed). Each survival curve reflects the trend from the collective data of individual patients, where each small perpendicular line along the survival curve corresponds to a single patient. Potential 3'UTR binding sites of miRNAs were found using the web-based tool www.targetscan.org.
  • TNFSF4 TNFSF4 above the median value was found to be associated with a significantly improved survival for all melanoma patients using a cutoff of 2 transcripts per million (Fig. 1A; TPM). This holds true for the subgroups of stage I II patients (Fig. IB; using a cutoff of 1.8 TPM), but is even more pronounced and significant for the subgroup of stage III patients (Fig. 1C; using a cutoff of 2.1 TPM) or the subgroup of stage IIIc/IV patients (Fig. ID; distant metastasis, cutoff 2.3 TPM).
  • TNFSF4 The expression of TNFSF4 was found to be significantly higher in malignant melanocytes than in other types of immune cells and endothelial cells, specifically, T-cells, B-cells, NK cells, cancer associated fibroblasts (CAFs), endothelial cells and macrophages (Fig. 2, in reads per kilobase per million (RPKM)).
  • CAFs cancer associated fibroblasts
  • Fig. 2 in reads per kilobase per million
  • TNFSF4 a significant variance in the expression of TNFSF4 between samples was observed. Non significant differences in expression of TNFSF4 were detected between ulcerated and non-ulcerated melanoma in either the primary tumor samples or in metastatic deposits originating from ulcerated or non- ulcerated tumors.
  • the expression of TNFSF4 was generally higher in metastatic samples than in primary tumors (Fig. 3, in transcripts per million (TPM)).
  • TNFSF4 mRNA and TNFSF4 protein were detected in most of the cell lines (Figs. IE and IF, respectively).
  • Ulceration a known prognostic factor in melanoma, was evaluated for its association with survival in the TCGA cohort. Whereas there was a statistically significant association between ulceration and worse prognosis in the entire cohort (Fig. 4A) and in a sub-group of stage II patients (Fig. 4B), the difference in overall survival in stage III patients between those with ulcerated (U) primaries vs. those with non-ulcerate (N) primaries was not statistically significant (Fig. 4C).
  • TNFSF4 The expression of TNFSF4 was assessed in tumor samples of 40 patients with metastatic melanoma receiving anti-PDl treatment.
  • PFS progression free survival
  • OS overall survival
  • TNFSF4 expression was found to be a marker for responsiveness to immunotherapy, especially to monotherapy.
  • Example 3 Expression of checkpoint mRNAs in melanoma
  • the immunological synapse - namely, the interface between immune cells and cancer cells or antigen presenting cells (APCs) - is multi-faceted and complex.
  • the following example relates to immune checkpoints on the melanoma/APC side of the immunological synapse.
  • the number of putative binding sites ranged from one to five in each of the mRNAs.
  • the data is provided in Table 3.
  • Table 3 Correlation between expression of mir-15a/16-l miRNAs and checkpoint mRNAs mRNA mir-497 mir-195 mir-503 mir-16-1 mir-424 mir-16-2 mir-15a mir-15-b
  • TNFSF4 0.21 0.15 0.28 0.13 0.26 0.16 0.08 0.01
  • TNFSF9 0.02- 0.04- 0.20 0.06- 0.23 0.04- 0.08 0.05-
  • PVRL2 0.07 0.09 0.09 0.05- 0.14 0.04- 0.03- 0.00
  • CD276 0.01 0.02- 0.03- 0.15- 0.01 0.10- 0.13- 0.04
  • VTCN1 0.00 0.01- 0.04 0.07- 0.02 0.07- 0.06- 0.05-
  • the positive correlations between mir-16 was corroborated in vitro for checkpoint mRNAs B7.1 , PD-L1 and PD-L2 (Figs. 7A-7C).
  • melanoma cell lines were used for the tissue culture experiments - SB2, WM852, SK-Mel, mel-793, A375, mel-1617, 451Lu, mel-526, mel-624, mel-1361A, eng- 003-mel, HS294T, MEWO, mel-14PA, mel-15A, mel-33-Al , mel-33-Bl.
  • melanoma cell lines (SB2, SK-mel, MEWO, mel-14PA, mel-1617 and mel-793) were transiently transfected with a plasmid expressing a small-interfering RNA to mir-16 (mir-16-siRNA): CGCCUUTUTTTUCGTGCTGCTU (SEQ ID NO:l) and GCGGUUAUAAAUGCACGACGAU (SEQ ID NO: 2) or to an unrelated sequence using LipofectinTM (control cells). 48 hours after transfection, RNA was extracted from the cells using the Total RNA purification kit (Norgen Biotek), and the expression of checkpoint mRNAs assessed by qRT-PCR.
  • mir-16 The levels of mir-16 were significantly lower in the trans fected cells compared to control cells (in which an irrelevant siRNA was transfected; results not shown).
  • mir-16 -deprived cell lines i.e. in mel-14PA, mel-1617, mel-793, MEWO and SB2
  • the expression levels of seven (7) checkpoint mRNAs increased compared to control cell lines (Fig. 11).
  • mir-16 acts to negatively regulate the expression of mRNAs, by targeting their 3'UTR directly or indirectly. This negative feedforward loop is predicted to maintain the levels of checkpoint mRNAs constant even in the face of cellular perturbations in the expression of the transcription factor that regulates the loop.
  • NF-kB was previously shown to regulate the transcription of mir-16, B7.1 and PD-1L.
  • Example 5 Down- regulation of mir-16 by pharmacologic and epigenetic modifiers
  • Melanoma cells were treated with the pharmacological inhibitor of MAP3K7 5Z-7- oxozeaenol (Sigma®) or the epigenetic modifiers 5-azacytidine and phenyl-butyric acid (PBA) and the level of checkpoint mRNAs were assessed by qRT-PCR.
  • Sigma® the pharmacological inhibitor of MAP3K7 5Z-7- oxozeaenol
  • PBA phenyl-butyric acid
  • NF-kB activation depends on MAP3K7, which phosphorylates and activates the IKK complex, leading to the phosphorylation, ubiquitination and degradation of NFKB1A. This frees NF- ⁇ , which is then activated, trans-located to the nucleus and activates transcription of multiple genes.
  • RNA with a complementary sequence to mir- 16 led to an increase and decrease in the levels of mir- 16, respectively, as expected (FIG.15C).
  • the levels of CD40 and CD80 mRNAs were not altered following transfection with the mir- 16-mimic but, surprisingly, were increased following transfection with a mir- 16-siRNA (FIGs. l5D-16E), indicating that inhibition of mir- 16 by means of small interfering RNAs increases the expression of CD40 and CD80 mRNAs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des méthodes de détection améliorée de mélanome, conduisant à l'optimisation d'un schéma de traitement de mélanome, et des méthodes de traitement d'un mélanome.
PCT/IL2018/050367 2017-03-30 2018-03-29 Méthodes de traitement de mélanome WO2018178989A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478647P 2017-03-30 2017-03-30
US62/478,647 2017-03-30

Publications (1)

Publication Number Publication Date
WO2018178989A1 true WO2018178989A1 (fr) 2018-10-04

Family

ID=63674671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2018/050367 WO2018178989A1 (fr) 2017-03-30 2018-03-29 Méthodes de traitement de mélanome

Country Status (1)

Country Link
WO (1) WO2018178989A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912831B1 (en) 2016-12-07 2021-02-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150191525A1 (en) * 2013-11-18 2015-07-09 Alan L. Epstein Ox40l fusion protein for the immunotherapy of tumors of veterinary animals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150191525A1 (en) * 2013-11-18 2015-07-09 Alan L. Epstein Ox40l fusion protein for the immunotherapy of tumors of veterinary animals

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AQEILAN, R. I. ET AL.: "miR-15a and miR-16-1 in cancer: discovery, function and future perspectives", CELL DEATH AND DIFFERENTIATION, vol. 17, no. 2, 5 June 2009 (2009-06-05), pages 215, XP055004117 *
DULOS, JOHN ET AL.: "PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer", JOURNAL OF IMMUNOTHERAPY, vol. 35, no. 2, 1 January 2012 (2012-01-01), pages 169 - 178, XP008171910, Retrieved from the Internet <URL:https://journals.lww.com/immunotherapy-journal/Abstract/2012/02000/PD_1_Blockade_Augments_Th1_and_Th17_and_Suppresses.8.aspx> *
GUO, SEN ET AL.: "Serum miR-16: a potential biomarker for predicting melanoma prognosis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 136, no. 5, 29 January 2016 (2016-01-29), pages 985 - 993, XP055550429, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0022202X16003651> *
MELERO, IGNACIO ET AL.: "Evolving synergistic combinations of targeted immunotherapies to combat cancer", NATURE REVIEWS CANCER, vol. 15, no. 8, 1 August 2015 (2015-08-01), pages 457, XP055316136, Retrieved from the Internet <URL:https://www.semanticscholar.org/paper/Evolving-synergistic-combinations-of-targeted-to-Melero-Berman/abf17d9398345400785bc035f46f11b650034235> *
MORRIS, NICHOLAS P. ET AL.: "Development and characterization of recombinant human Fc: OX40L fusion protein linked via a coiled-coil trimerization domain", MOLECULAR IMMUNOLOGY, vol. 44, no. 12, 31 May 2007 (2007-05-31), pages 3112 - 3121, XP022031616, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950941> *
OTT ET AL.: "CTLA-4 and PD-1/PD-Ll blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients", 30 October 2013 (2013-10-30), XP055200528, Retrieved from the Internet <URL:http://clincancerres.aacijournals.org/content/19/19/5300> *
SIMEONE, ESTER ET AL.: "Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti- CD 137, and anti-PD 1", JOURNAL OF IMMUNOTOXICOLOGY, vol. 9.3, 17 March 2012 (2012-03-17), pages 241 - 247, XP009181173, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/full/10.3109/1547691X.2012.678021> *
SNYDER, ALEXANDRA ET AL.: "Genetic basis for clinical response to CTLA-4 blockade in melanoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, no. 23, 4 December 2014 (2014-12-04), pages 2189 - 2199, XP055262135, Retrieved from the Internet <URL:https://www.nejm.org/doi/full/10.1056/NEJMoa1406498> *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912831B1 (en) 2016-12-07 2021-02-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11638755B2 (en) 2016-12-07 2023-05-02 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US12246066B2 (en) 2016-12-07 2025-03-11 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
Hua et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis
EP3639170B1 (fr) Systèmes et procédés d&#39;identification de répondeurs et de non-répondeurs à une thérapie de blocage de points de contrôle immunitaires
US20200063188A1 (en) Biomarkers for inflammatory skin disease
US20230302035A1 (en) Repeat rna as biomarkers of tumor immune response
Dai et al. LINC00665 functions as a competitive endogenous RNA to regulate AGTR1 expression by sponging miR-34a-5p in glioma
Li et al. Elevated linc00936 or silenced microRNA-425-3p inhibits immune escape of gastric cancer cells via elevation of ZC3H12A
US20220396840A1 (en) Iron-score and in vitro method for identifying mantle cell lymphoma (mcl) subjects and therapeutic uses and methods
AU2014322824A1 (en) Cancer biomarker and diagnostic
JP2025501311A (ja) 自然免疫活性化因子に応答するための転写バイオマーカー
Li et al. NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction
WO2018178989A1 (fr) Méthodes de traitement de mélanome
WO2020082037A1 (fr) Méthodes de traitement d&#39;un sous-type de cancer du poumon à petites cellules
Li et al. MicroRNA-371-5p targets SOX2 in gastric cancer
EP1946117B1 (fr) P66-shc en tant que marqueur de prédiction dans le traitement du cancer
US20110206689A1 (en) Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof
US20220081719A1 (en) Method and application thereof for predicting prognosis of cancer
KR20180092135A (ko) 대장암 및 직장암의 예방, 진단 또는 치료를 위한 ｖｌｄｌｒ의 용도
Xu et al. Potassium voltage‑gated channel subfamily E member 4 facilitates the malignant progression of colon cancer by enhancing EGF containing fibulin extracellular matrix protein 2 expression
US9874565B2 (en) Oncogene associated with human cancers and methods of use thereof
US20070254303A1 (en) Methods for assessing the efficacy of treatment with a glucocorticoid
CN116676385B (zh) Linc02096在作为预测食管癌免疫治疗效果、预后的标志物及治疗靶点中的应用
US20240124568A1 (en) Chemerin inhibitors and uses thereof for treating kidney cancer
US20240158871A1 (en) Pan-Cancer Classification Based on FMRP Pathway Activity that Informs Differential Prognosis and Therapeutic Responses
Szeto et al. P3. 04-14 TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients
Hassan The Relationship Between Obesity and Breast Cancer on the Molecular Level

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18775367

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18775367

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载